Dan Hoth, M.D.
Dr. Daniel F. Hoth, M.D., is a clinical and drug development veteran with more than 30 years of experience. He also serves as chief medical advisor at Confluence Life Sciences Inc. and as president of Hoth Consulting, where he provides drug development and clinical trial consulting services to pharmaceutical and biotechnology companies. Dr. Hoth previously served as acting chief medical officer of Semafore Pharmaceuticals Inc. and, before that, as senior vice president and chief medical officer at AXYS Pharmaceuticals Inc. Prior to joining AXYS, Dr. Hoth was the principal of an Independent consulting practice to pharmaceutical and life science firms and the National Institute of Health. He also has served as senior vice president and chief medical officer at Cell Genesys Inc., where he was responsible for trials of gene therapy in cancer and HIV, and led the Division of Acquired Immunodeficiency Syndrome at the National Institute of Health, heading all activities under the NIAID’s AIDS program. From 1980 to 1987, Dr. Hoth served as the Chief of Investigational Drug Branch of the National Cancer Institute (NCI), responsible for all clinical investigations of IND stage anticancer pharmaceuticals. From 1981 to 1993, he held various positions at the National Institutes of Health (NIH), including the head of the Cancer Therapy Evaluation Program. He also served as Consultant of NIH and FDA. Dr. Hoth served as an instructor and Assistant Professor of Medicine at Georgetown University School of Medicine. Dr. Hoth serves as a Director of Symphony Evolution, Inc. and Acologix, Inc. Dr. Hoth earned a medical degree from Georgetown University School of Medicine and completed his Fellowship in medical oncology at Georgetown University Hospital. He also holds A.B. degree in Psychology from Franklin and Marshall College.